NeoGenomics, Inc. logo

NEO

NeoGenomics, Inc.

$10.12

Earnings Summary

Revenue
$128.78Mn
Net Profits
$-36.85Mn
Net Profit Margins
-28.62%

Highlights

Revenue:

NeoGenomics, Inc.’s revenue jumped 6.13% since last year same period to $128.78Mn in the Q3 2022. On a quarterly growth basis, NeoGenomics, Inc. has generated 2.97% jump in its revenue since last 3-months.

Net Profits:

NeoGenomics, Inc.’s net profit fell -81.11% since last year same period to $-36.85Mn in the Q3 2022. On a quarterly growth basis, NeoGenomics, Inc. has generated -4.39% fall in its net profits since last 3-months.

Net Profit Margins:

NeoGenomics, Inc.’s net profit margin fell -70.64% since last year same period to -28.62% in the Q3 2022. On a quarterly growth basis, NeoGenomics, Inc. has generated -1.38% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the NeoGenomics, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.19
EPS Estimate Current Year
-0.19

Highlights

EPS Estimate Current Quarter:

NeoGenomics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.19 - a 8.61% jump from last quarter’s estimates.

EPS Estimate Current Year:

NeoGenomics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.19.

Key Ratios

Key ratios of the NeoGenomics, Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
-0.16
Return on Assets (ROA)
-0.05
Return on Equity (ROE)
-0.15

Highlights

Earning Per Share (EPS):

NeoGenomics, Inc.’s earning per share (EPS) fell -1500% since last year same period to -0.16 in the Q2 2022. This indicates that the NeoGenomics, Inc. has generated -1500% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. NeoGenomics, Inc.’s return on assets (ROA) stands at -0.05.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. NeoGenomics, Inc.’s return on equity (ROE) stands at -0.15.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-02-25
-0.15
-0.14
7.22%
2021-05-06
0.01
-0.04
-549.44%
2021-08-09
-0.01
-0.01
24.81%
2021-11-04
-0.09
-0.08
11.11%

Company Information

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Organisation
NeoGenomics, Inc.
Headquarters
9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
Employees
2000
Industry
Health Services

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*